The OncLive Immunotherapy in GU Cancers condition center page is a comprehensive resource for clinical news and expert insights on available and investigational immunotherapies in genitourinary malignancies, specifically prostate cancer, urothelial carcinoma, and renal cell carcinoma. This page features news articles, interviews in written and video format, and podcasts that focus on updates with checkpoint inhibitors and the ongoing research with this type of treatment.
April 1st 2024
Durvalumab in combination with guadecitabine was tolerable and led to a PFS benefit in patients with checkpoint inhibitor-naive ccRCC.
Avelumab/Axitinib Combo Improves PFS in Frontline RCC
September 11th 2018Combining the PD-L1 inhibitor avelumab with the VEGF inhibitor axitinib significantly improved progression-free survival compared with sunitinib in treatment-naïve patients with advanced renal cell carcinoma, according to findings from the phase III JAVELIN Renal 101 study.
Dr. Balar Discusses Study of Immunotherapy Combination in Bladder Cancer
September 6th 2018Arjun V. Balar, MD, assistant professor, Department of Medicine, director, Genitourinary Medical Oncology Program, NYU Langone’s Perlmutter Cancer Center, discusses a study of an immunotherapy combination in bladder cancer.
Enfortumab Vedotin Emerging as Post-Immunotherapy Option in Bladder Cancer
Jonathan E. Rosenberg, MD, discusses the promise of enfortumab vedotin in patients with bladder cancer who previously received a checkpoint inhibitor, and reflects on the rapid pace of change in the urothelial cancer landscape.
Dr. Grivas on the IMvigor211 Trial in Metastatic Urothelial Carcinoma
August 8th 2018Petros Grivas, MD, PhD, director, University of Washington Medicine’s Genitourinary Cancers Program, associate professor, Oncology, University of Washington, Seattle Cancer Care Alliance, discusses the IMvigor211 trial in metastatic urothelial carcinoma.
Dr. Choueiri Discusses Checkpoint Inhibitors in RCC
July 4th 2018Toni Choueiri, MD, director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, Jerome and Nancy Kohlberg Associate Professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses checkpoint inhibitors in renal cell carcinoma (RCC).
Findings Set Stage for Expanded Immunotherapy Role in Bladder Cancer
June 26th 2018Researchers now are turning their attention toward earlier disease settings involving patients who are refractory to standard therapies in nonmuscle-invasive bladder cancer or who are poor candidates for surgery in muscle-invasive bladder cancer.
FDA Adds PD-L1 Expression to Frontline Pembrolizumab, Atezolizumab Urothelial Carcinoma Labels
The FDA has incorporated PD-L1 status into the labels for pembrolizumab (Keytruda) and atezolizumab (Tecentriq) for existing frontline approvals for platinum-ineligible patients with urothelial carcinoma.
Dr. Grivas on Immunotherapy in Advanced Urothelial Cancer
June 19th 2018Petros Grivas, MD, PhD, director, University of Washington Medicine’s Genitourinary Cancers Program, associate professor, Oncology, University of Washington, Seattle Cancer Care Alliance, discusses the use of immunotherapy in patients with advanced urothelial cancer.
Dr. Gupta on Phase Ib/II Trial of Pembrolizumab With Bevacizumab in RCC
June 14th 2018Shilpa Gupta, MD, assistant professor of medicine, Hematology/Oncology and Transplantation Division, University of Minnesota, discusses the phase Ib/II studies of pembrolizumab with bevacizumab for the treatment of patients with metastatic renal cell carcinoma.
FDA Warns Against Single-Agent Checkpoint Inhibition for PD-L1-Low Untreated Urothelial Carcinoma
The FDA has issued a drug safety notification warning against the use of frontline single-agent immune checkpoint inhibition for patients with PD-L1–low expressing platinum-eligible urothelial carcinoma.
Biomarker Dilemma Persists With Immunotherapy in Bladder Cancer
May 15th 2018The quest continues to identify a predictive biomarker of response to more precisely treat patients with checkpoint inhibitors that, while markedly beneficial to some patients, are not without their own costs and associated immune-related adverse effects.